Bausch + Lomb (BLCO) BL1332 Misses Phase 2 Primary Endpoint

Bausch + Lomb's (BLCO) Phase 2 study for BL1332 missed its primary endpoint, showing no statistically significant improvement over the vehicle. The LS mean differences were -11.5 and -9.0, favoring BL1332 but not reaching significance. A 0.30% dose showed nominal significance at six hours for a secondary endpoint, with adverse event rates reported but no serious events.

Original reporting
Published Nov 19, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bausch + Lomb (BLCO) BL1332 Misses Phase 2 Primary Endpoint — source image
Decision brief

The 30-second read

$BLCOBearishMed
01

Why it matters

A primary endpoint miss typically reduces the probability of advancement or label-enabling evidence, increasing uncertainty around timelines and future capital needs.

02

Market read

Traders can reassess BL1332’s development odds and the near-term risk premium for BLCO based on the primary endpoint miss.

03

What to watch

The article does not provide safety severity details beyond rates, nor does it clarify trial design, sample size, or whether the miss was close to significance, which could moderate the market reaction.

Relevance 8/10Novelty 8/10Timing: reported late day, for next-session biotech risk repricing

Background

The piece summarizes a Phase 2 readout for Bausch + Lomb’s BL1332, focusing on endpoint significance versus vehicle.

Company-level read

Ticker impact

$BLCOBearishHigh confidence
Context

Bausch + Lomb’s BL1332 Phase 2 trial missed the primary endpoint, with no statistically significant improvement versus vehicle.

Expected impact

Likely downside bias as traders price reduced probability of future development success and potential partner or financing risk.

Evidence & confidence

The article explicitly states the primary endpoint was not statistically significant versus vehicle, which is a direct negative clinical readout.

Market effects

Adds to the evidence of higher clinical-development risk for ophthalmology/biopharma programs, potentially weighing on peer sentiment.

Limited, mostly affects US-listed biotech sentiment rather than broad regional flows.

Low, as the catalyst is company-specific clinical trial efficacy.

Counterpoint

Secondary and exploratory signals (including complete relief at six hours) could keep optionality alive for further dose refinement or subgroup analyses.

Key entities

  • Bausch + Lomb

    US-listed ophthalmic drug developer; subject of the Phase 2 BL1332 efficacy readout.

  • BL1332

    Bausch + Lomb Phase 2 candidate evaluated against vehicle with primary and secondary endpoints.

Related articles

$BLCOMedAI 8/10

What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call

Bausch + Lomb (BLCO) reported Q3 earnings, highlighting growth across multiple franchises. Adjusted gross margin rose to 64.7%, with operating cash flow at $233M. The company raised its 2026 revenue outlook to $5.45B-$5.55B and adjusted EBITDA guidance to $1.09B-$1.14B. Interim CEO Appio focused on profitability and R&D pipeline advancements.

$BLCOHighAI 8/10

Bausch & Lomb Corp (BLCO) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth

Bausch & Lomb Corp (BLCO) reported Q3 2026 revenue growth of 8%, with all segments showing gains. Adjusted EBITDA rose 34% to $325M. The company raised full-year revenue and EBITDA guidance. Key products like MIBO and Lumify saw strong growth, while surgical equipment revenue declined 11%. The company faces regulatory and competitive pressures. Leadership changes were announced, with Tom Appio becoming interim CEO.

$BLCOHighAI 8/10

Bausch + Lomb Soars 16% on Big Q3 Profit Beat and Raised Full-Year Guidance

Bausch + Lomb's shares rose 16% after Q3 earnings beat expectations, with adjusted EPS at $0.34 vs. $0.22 consensus and revenue up 7% to $1.375B. Adjusted EBITDA increased 34% to $325M, and the company raised its full-year EBITDA guidance by $65M. Key growth drivers included MIEBO, LUMIFY, and premium intraocular lenses. Johnson & Johnson's contact lens sales also grew, contrasting with Cooper Companies' flat sales.

$BLCOMed

Bausch + Lomb: Q3 Earnings Snapshot

Bausch + Lomb (BLCO) reported Q3 net income of $32M, or 9 cents per share, beating estimates. Adjusted EPS was 34 cents. Revenue was $1.38B, also topping forecasts. The company expects full-year revenue of $5.45B-$5.55B. Shares are up 14% YTD and 26% over 12 months.